Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Скринер
Новости
О нас

PLSE - Pulse Biosciences, Inc. Последние новости | Finranks

Home

/

PLSE

P

Pulse Biosciences, Inc. (PLSE)

NCM – Цена в реальном времени. Валюта: USD

23.30

+4.22 (22.12%)

При закрытии: May 12, 2026, 4:00 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

ATM Equity Purchases by Pulse Biosciences' Co-Chairmen Total Approximately $13.3 Million

ATM Equity Purchases by Pulse Biosciences' Co-Chairmen Total Approximately $13.3 Million

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced its Co-Chairmen of the Board, Robert Duggan and Chief Executive Officer Paul LaViolette, completed purchases of Pulse Biosciences' common stock through its at-the-market equity offering program (ATM) during the Company's designated trading window. In total, the Co-Chairmen acquired 675,233 shares of Pulse Bi.

Pulse Biosciences Q1 Earnings Call Highlights

Pulse Biosciences Q1 Earnings Call Highlights

Pulse Biosciences NASDAQ: PLSE said it is sharpening its focus on its nanosecond pulsed field ablation platform for atrial fibrillation after reporting first-quarter 2026 results and highlighting new clinical data from its cardiac catheter program.

Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference

Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced plans to participate in the upcoming BofA Securities 2026 Healthcare Conference in Las Vegas, NV. Pulse Biosciences' Management is scheduled to present on Wednesday, May 13, at 4:35 pm PT. A live and recorded webcast of the presentation will be available on the “Events Calendar and Presentations” page of the.

Pulse Biosciences, Inc. (PLSE) Q1 2026 Earnings Call Transcript

Pulse Biosciences, Inc. (PLSE) Q1 2026 Earnings Call Transcript

Pulse Biosciences, Inc. (PLSE) Q1 2026 Earnings Call Transcript

Pulse Biosciences (PLSE) Upgraded to Buy: What Does It Mean for the Stock?

Pulse Biosciences (PLSE) Upgraded to Buy: What Does It Mean for the Stock?

Pulse Biosciences (PLSE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Pulse Biosciences, Inc (PLSE) Reports Q1 Loss, Lags Revenue Estimates

Pulse Biosciences, Inc (PLSE) Reports Q1 Loss, Lags Revenue Estimates

Pulse Biosciences, Inc (PLSE) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to a loss of $0.17 per share a year ago.

Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results

Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced business updates and financial results for the first quarter ended March 31, 2026. Recent Business Highlights Endocardial Catheter AF Ablation Announced strategic prioritization of the nPulse Cardiac Catheter System following landmark clinical data, presented at AF Symposium, demonst.

Видео

No Data

There is no data to display

Пресс-релизы

ATM Equity Purchases by Pulse Biosciences' Co-Chairmen Total Approximately $13.3 Million

ATM Equity Purchases by Pulse Biosciences' Co-Chairmen Total Approximately $13.3 Million

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced its Co-Chairmen of the Board, Robert Duggan and Chief Executive Officer Paul LaViolette, completed purchases of Pulse Biosciences' common stock through its at-the-market equity offering program (ATM) during the Company's designated trading window. In total, the Co-Chairmen acquired 675,233 shares of Pulse Bi.

Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results

Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced business updates and financial results for the first quarter ended March 31, 2026. Recent Business Highlights Endocardial Catheter AF Ablation Announced strategic prioritization of the nPulse Cardiac Catheter System following landmark clinical data, presented at AF Symposium, demonst.

Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026

Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced late-breaking positive clinical data from its nPulse Cardiac Catheter System first-in-human feasibility study at the Heart Rhythm 2026 meeting. The late-breaking presentation included incremental participant follow up data. Building upon the previously reported data set presented at.

Pulse Biosciences' nPulse™ Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting

Pulse Biosciences' nPulse™ Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation™ (nsPFA™) energy, today announced that its nPulse™ Cardiac Catheter will be prominently featured during the Heart Rhythm Society (HRS) 2026 Annual Meeting, taking place April 23-26 in Chicago, Illinois. At HRS 2026, Pulse Biosciences will present late‑breaking clinical trial updates, highlighting European feasibility study one‑year outcomes.